Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53719, USA.
Molecules. 2023 Mar 25;28(7):2950. doi: 10.3390/molecules28072950.
PLK1 is a protein kinase that regulates mitosis and is both an important oncology drug target and a potential antitarget of drugs for the DNA damage response pathway or anti-infective host kinases. To expand the range of live cell NanoBRET target engagement assays to include PLK1, we developed an energy transfer probe based on the anilino-tetrahydropteridine chemotype found in several selective PLK inhibitors. Probe was used to configure NanoBRET target engagement assays for PLK1, PLK2, and PLK3 and measure the potency of several known PLK inhibitors. In-cell target engagement for PLK1 was in good agreement with the reported cellular potency for the inhibition of cell proliferation. Probe enabled the investigation of the promiscuity of adavosertib, which had been described as a dual PLK1/WEE1 inhibitor in biochemical assays. Live cell target engagement analysis of adavosertib via NanoBRET demonstrated PLK activity at micromolar concentrations but only selective engagement of WEE1 at clinically relevant doses.
PLK1 是一种调节有丝分裂的蛋白激酶,它既是肿瘤学药物的重要靶点,也是 DNA 损伤反应途径或抗感染宿主激酶药物的潜在抗靶标。为了将活细胞 NanoBRET 靶标结合测定的范围扩展到包括 PLK1,我们开发了一种基于几种选择性 PLK 抑制剂中发现的苯胺四氢喋呤化学型的能量转移探针。探针 用于配置针对 PLK1、PLK2 和 PLK3 的 NanoBRET 靶标结合测定,并测量几种已知 PLK 抑制剂的效力。PLK1 的细胞内靶标结合与抑制细胞增殖的报道细胞效力一致。探针 使人们能够研究 adavosertib 的混杂性,在生化测定中,avadosertib 被描述为一种双重 PLK1/WEE1 抑制剂。通过 NanoBRET 进行的 adavosertib 的活细胞靶标结合分析表明,在微摩尔浓度下具有 PLK 活性,但仅在临床相关剂量下选择性结合 WEE1。